Abstract：Objective To explore overall survival（OS）and progression free survival（PFS）Thalidomide，Lenalidomide and Bortezomib in the treatment of patients with multiple myeloma and analyze prognosis related factors. Methods A retrospective analysis wasmade on 42 cases ofmultiplemyeloma in our hospital from January 2010 to January 2015.The parameterswere analyzed by single factor，the single factor analysiswas carried out by Coxmodel，and the parameters of statistical significance were analyzed by multiple factors regression analysis，and the survival curve was constructed.Results Median survival time was 43.36 months，OS rate for 2 years was 76.19%，with 42.86%for 3 years.In single factor analysis，age，serum creatinine，LDH，β2-MG，ISS stage，serum free light chain ratio of normal or not after treatment and effect were associated with OS，age and effect were associated with PFS.Conclusion Serum free light chain ratio and the depth of treatment are associated with OS after treatment for patients with multiple myeloma，Thalidomide，Lenalidomide and Bortezomib treatment can significantly improve OSof patients.
Anderson KC，Alsina M，Atanackovic D，et al.Multiple Myeloma，version 2.2016：clinical practice guidelines in oncology［J］.JNatl Compr Canc Netw，2015，13（11）：1398-1435.
［3］
Greipp PR，San Migue IJ，Durie BG，et al.International staging system for multiple myeloma［J］.JClin Oncol，2005，23 （12）：3412-3420.
［4］
Iwama K，Chihara D，Tsuda K，et al.Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiplemyeloma［J］.Eur JHaematol，2013，29（10）：134-141.
［5］
Broyl A，Hose D，Lokhorst H，et al.Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients［J］.Blood，2010，116（14）：2543-2553.
［6］
vet Loiseau H，Durie BG，Cavo M，et al.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma：an International Myeloma Working Group collaborative project［J］.Leukemia，2013，27 （3）：711-717.
［7］
Ladetto M，Pagliano G，Ferrero S，et al.Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib，thalidomide，and dexamethasone in patients with autografted myeioma［J］.J Clin Oncol，2010，28（12）：2077-2084.
［8］
Martinez-Lopez J，Blade J，Mateos MV，et al.Long term prognostic significance of response in multiplemyeloma after stem cell transplantation［J］.Blood，2011，118（3）：529-534.
［9］
Moreau P，Attal M，PégouriéB，et al.Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial［J］.Blood，2011，117 （11）：3041-3044.
［10］
Paiva B，Martinez-Lopez J，Vidriales MB，et al.Comparison of immunofixation，serum free light chain，and immunophenotyping for response evaluation and prognostication in multiple myeloma［J］.JClin Oncol，2011，29（12）：1627-1633.
［11］
Murng SH，Follows L，Whitfield P，et al.Defining the impact of individual sample variability on routine immunoassay of serum free light chains （sFLC）in multiplemyeloma［J］.Clin Exp Immunol，2013，171（2）：201-209.
［12］
An N，Li X，Shen M，et al.Analysis of clinical features，treatment response，and prognosis among 61 elderly newly diagnosed multiple myeloma patients：a single-center report［J］.World JSurg Oncol，2015，13：239.
京公网安备 11010502046607号